{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:18:24Z","timestamp":1791818304213,"version":"4.3.4"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Frankfurt"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Trials have shown promising clinical activity of the selective SYK inhibitor entospletinib in patients with high expressing <jats:italic>HOXA9\/MEIS1<\/jats:italic> acute leukemias. As the development of resistance mechanisms is a common problem in the use of targeted drugs, we performed a chemical library screen to identify drug sensitivities in SYK inhibitor resistant AML cells. We identified that SYK inhibitor resistant cells displayed an increased sensitivity to glucocorticoids. Glucocorticoids are potent immunosuppressants which work in part by inhibiting the transcription of cytokine genes. RNA sequencing of entospletinib resistant cells revealed a strong enrichment of inflammatory response and TNF\u03b1 signaling via NF-\u03baB gene sets in comparison to naive cells. Naive AML cells treated with entospletinib showed a strong downregulation of the same gene sets which were upregulated in the resistant state. Our data suggest that inflammatory signaling pathways play a role in entospletinib resistant AML cells.<\/jats:p>","DOI":"10.1038\/s41598-025-96660-w","type":"journal-article","created":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T07:54:02Z","timestamp":1743839642000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Inflammatory signaling pathways play a role in SYK inhibitor resistant AML"],"prefix":"10.1038","volume":"15","author":[{"given":"Sarah","family":"Tausch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Villinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Alexe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel J.","family":"Urban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Vischedyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Scheich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Serve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Stegmaier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Oellerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anjali","family":"Cremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,5]]},"reference":[{"key":"96660_CR1","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/ajh.26822","volume":"98","author":"S Shimony","year":"2023","unstructured":"Shimony, S., Stahl, M. & Stone, R. M. Acute myeloid leukemia: 2023 update on diagnosis, risk-stratification, and management. Am. J. Hematol. 98, 502\u2013526. https:\/\/doi.org\/10.1002\/ajh.26822 (2023).","journal-title":"Am. J. Hematol."},{"key":"96660_CR2","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrc2253","volume":"7","author":"AV Krivtsov","year":"2007","unstructured":"Krivtsov, A. V. & Armstrong, S. A. MLL translocations, histone modifications and leukaemia stem-cell development. Nat. Rev. Cancer. 7, 823\u2013833. https:\/\/doi.org\/10.1038\/nrc2253 (2007).","journal-title":"Nat. Rev. Cancer"},{"key":"96660_CR3","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.ccell.2017.03.001","volume":"31","author":"S Mohr","year":"2017","unstructured":"Mohr, S. et al. Hoxa9 and Meis1 cooperatively induce addiction to Syk signaling by suppressing miR-146a in acute myeloid leukemia. Cancer Cell 31, 549\u2013562e511, (2017). https:\/\/doi.org\/10.1016\/j.ccell.2017.03.001","journal-title":"Cancer Cell"},{"key":"96660_CR4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1182\/blood-2005-02-0560","volume":"106","author":"M Alcalay","year":"2005","unstructured":"Alcalay, M. et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc\u2009+\u2009AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 106, 899\u2013902. https:\/\/doi.org\/10.1182\/blood-2005-02-0560 (2005).","journal-title":"Blood"},{"key":"96660_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00826","author":"GC Issa","year":"2024","unstructured":"Issa, G. C. et al. Menin Inhibition with revumenib for KMT2A-Rearranged relapsed or refractory acute leukemia (AUGMENT-101). J. Clin. Oncol.. https:\/\/doi.org\/10.1200\/JCO.24.00826 (2024).","journal-title":"J. Clin.Oncol."},{"key":"96660_CR6","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.ccr.2009.08.018","volume":"16","author":"CK Hahn","year":"2009","unstructured":"Hahn, C. K. et al. Proteomic and genetic approaches identify Syk as an AML target. Cancer Cell. 16, 281\u2013294. https:\/\/doi.org\/10.1016\/j.ccr.2009.08.018 (2009).","journal-title":"Cancer Cell."},{"key":"96660_CR7","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1182\/blood.v97.4.1050","volume":"97","author":"Y Kuno","year":"2001","unstructured":"Kuno, Y. et al. Constitutive kinase activation of the TEL-Syk fusion gene in myelodysplastic syndrome with t(9;12)(q22;p12). Blood 97, 1050\u20131055. https:\/\/doi.org\/10.1182\/blood.v97.4.1050 (2001).","journal-title":"Blood"},{"key":"96660_CR8","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1038\/sj.leu.2403266","volume":"18","author":"T Kanie","year":"2004","unstructured":"Kanie, T. et al. TEL-Syk fusion constitutively activates PI3-K\/Akt, MAPK and JAK2-independent STAT5 signal pathways. Leukemia 18, 548\u2013555. https:\/\/doi.org\/10.1038\/sj.leu.2403266 (2004).","journal-title":"Leukemia"},{"key":"96660_CR9","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1182\/blood-2012-09-457887","volume":"121","author":"T Oellerich","year":"2013","unstructured":"Oellerich, T. et al. beta2 integrin-derived signals induce cell survival and proliferation of AML blasts by activating a Syk\/STAT signaling axis. Blood 121, 3889\u20133899. https:\/\/doi.org\/10.1182\/blood-2012-09-457887 (2013). S3881-3866.","journal-title":"Blood"},{"key":"96660_CR10","doi-asserted-by":"publisher","first-page":"25575","DOI":"10.18632\/oncotarget.4669","volume":"6","author":"K Boros","year":"2015","unstructured":"Boros, K. et al. Increased SYK activity is associated with unfavorable outcome among patients with acute myeloid leukemia. Oncotarget 6, 25575\u201325587. https:\/\/doi.org\/10.18632\/oncotarget.4669 (2015).","journal-title":"Oncotarget"},{"key":"96660_CR11","doi-asserted-by":"publisher","first-page":"5852","DOI":"10.1158\/1078-0432.CCR-20-1064","volume":"26","author":"AR Walker","year":"2020","unstructured":"Walker, A. R. et al. Entospletinib in combination with induction chemotherapy in previously untreated acute myeloid leukemia: Response and predictive significance of HOXA9 and MEIS1 expression. Clin. Cancer Res. 26, 5852\u20135859. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-1064 (2020).","journal-title":"Clin. Cancer Res."},{"key":"96660_CR12","doi-asserted-by":"publisher","first-page":"3617","DOI":"10.1038\/onc.2014.314","volume":"34","author":"P Ramos","year":"2015","unstructured":"Ramos, P. & Bentires-Alj, M. Mechanism-based cancer therapy: Resistance to therapy, therapy for resistance. Oncogene 34, 3617\u20133626. https:\/\/doi.org\/10.1038\/onc.2014.314 (2015).","journal-title":"Oncogene"},{"key":"96660_CR13","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1158\/2159-8290.CD-19-0209","volume":"10","author":"A Cremer","year":"2020","unstructured":"Cremer, A. et al. Resistance mechanisms to SYK Inhibition in acute myeloid leukemia. Cancer Discov. 10, 214\u2013231. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0209 (2020).","journal-title":"Cancer Discov."},{"key":"96660_CR14","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1056\/NEJMoa1609783","volume":"376","author":"H Kantarjian","year":"2017","unstructured":"Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836\u2013847. https:\/\/doi.org\/10.1056\/NEJMoa1609783 (2017).","journal-title":"N. Engl. J. Med."},{"key":"96660_CR15","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaz0463","author":"J Vadakekolathu","year":"2020","unstructured":"Vadakekolathu, J. et al. Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia. Sci. Transl Med.. https:\/\/doi.org\/10.1126\/scitranslmed.aaz0463 (2020).","journal-title":"Sci. TranslMed."},{"key":"96660_CR16","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1182\/bloodadvances.2021004962","volume":"6","author":"S Stratmann","year":"2022","unstructured":"Stratmann, S. et al. Transcriptomic analysis reveals proinflammatory signatures associated with acute myeloid leukemia progression. Blood Adv. 6, 152\u2013164. https:\/\/doi.org\/10.1182\/bloodadvances.2021004962 (2022).","journal-title":"Blood Adv."},{"key":"96660_CR17","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1158\/2159-8290.CD-21-0956","volume":"12","author":"JM Ellegast","year":"2022","unstructured":"Ellegast, J. M. et al. Unleashing cell-Intrinsic inflammation as a strategy to kill AML blasts. Cancer Discov. 12, 1760\u20131781. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0956 (2022).","journal-title":"Cancer Discov."},{"key":"96660_CR18","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1124\/mol.119.115964","volume":"96","author":"TD Lee","year":"2019","unstructured":"Lee, T. D. et al. A High-Throughput screen of a library of therapeutics identifies cytotoxic substrates of P-glycoprotein. Mol. Pharmacol. 96, 629\u2013640. https:\/\/doi.org\/10.1124\/mol.119.115964 (2019).","journal-title":"Mol. Pharmacol."},{"key":"96660_CR19","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1056\/NEJMra050541","volume":"353","author":"T Rhen","year":"2005","unstructured":"Rhen, T. & Cidlowski, J. A. Antiinflammatory action of glucocorticoids-new mechanisms for old drugs. N. Engl. J. Med. 353, 1711\u20131723. https:\/\/doi.org\/10.1056\/NEJMra050541 (2005).","journal-title":"N. Engl. J. Med."},{"key":"96660_CR20","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/leu.2016.314","volume":"31","author":"D Malani","year":"2017","unstructured":"Malani, D. et al. Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML. Leukemia 31, 1187\u20131195. https:\/\/doi.org\/10.1038\/leu.2016.314 (2017).","journal-title":"Leukemia"},{"key":"96660_CR21","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1182\/blood.2019003124","volume":"136","author":"MT Gebru","year":"2020","unstructured":"Gebru, M. T. et al. Glucocorticoids enhance the antileukemic activity of FLT3 inhibitors in FLT3-mutant acute myeloid leukemia. Blood 136, 1067\u20131079. https:\/\/doi.org\/10.1182\/blood.2019003124 (2020).","journal-title":"Blood"},{"key":"96660_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.exphem.2010.11.009","volume":"39","author":"N Jiang","year":"2011","unstructured":"Jiang, N. et al. BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. Exp. Hematol. 39, 321\u2013329. https:\/\/doi.org\/10.1016\/j.exphem.2010.11.009 (2011).","journal-title":"Exp. Hematol."},{"key":"96660_CR23","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.immuni.2006.10.010","volume":"25","author":"J Schulze-Luehrmann","year":"2006","unstructured":"Schulze-Luehrmann, J. & Ghosh, S. Antigen-receptor signaling to nuclear factor kappa B. Immunity 25, 701\u2013715. https:\/\/doi.org\/10.1016\/j.immuni.2006.10.010 (2006).","journal-title":"Immunity"},{"key":"96660_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu, H., Lin, L., Zhang, Z., Zhang, H. & Hu, H. Targeting NF-kappaB pathway for the therapy of diseases: Mechanism and clinical study. Signal. Transduct. Target. Ther. 5, 209. https:\/\/doi.org\/10.1038\/s41392-020-00312-6 (2020).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"96660_CR25","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/s41392-020-00312-6","volume":"31","author":"Y Chen","year":"2017","unstructured":"Chen, Y. et al. MLL2, Not MLL1, Plays a major role in sustaining MLL-rearranged acute myeloid leukemia. Cancer Cell 31, 755\u2013770. https:\/\/doi.org\/10.1016\/j.ccell.2017.05.002 (2017).","journal-title":"Cancer Cell"},{"key":"96660_CR26","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.ccr.2013.05.004","volume":"24","author":"PG Miller","year":"2013","unstructured":"Miller, P. G. et al. In vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. Cancer Cell. 24, 45\u201358. https:\/\/doi.org\/10.1016\/j.ccr.2013.05.004 (2013).","journal-title":"Cancer Cell."},{"key":"96660_CR27","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.cell.2008.01.020","volume":"132","author":"MS Hayden","year":"2008","unstructured":"Hayden, M. S. & Ghosh, S. Shared principles in NF-kappaB signaling. Cell 132, 344\u2013362. https:\/\/doi.org\/10.1016\/j.cell.2008.01.020 (2008).","journal-title":"Cell"},{"key":"96660_CR28","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.4049\/jimmunol.173.2.1066","volume":"173","author":"Y Takada","year":"2004","unstructured":"Takada, Y. & Aggarwal, B. B. TNF activates Syk protein tyrosine kinase leading to TNF-induced MAPK activation, NF-kappaB activation, and apoptosis. J. Immunol. 173, 1066\u20131077. https:\/\/doi.org\/10.4049\/jimmunol.173.2.1066 (2004).","journal-title":"J. Immunol."},{"key":"96660_CR29","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/mt.2013.19","volume":"21","author":"AA Wilson","year":"2013","unstructured":"Wilson, A. A. et al. Lentiviral delivery of RNAi for in vivo lineage-specific modulation of gene expression in mouse lung macrophages. Mol. Ther. 21, 825\u2013833. https:\/\/doi.org\/10.1038\/mt.2013.19 (2013).","journal-title":"Mol. Ther."},{"key":"96660_CR30","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1126\/science.278.5339.860","volume":"278","author":"F Mercurio","year":"1997","unstructured":"Mercurio, F. et al. IKK-1 and IKK-2: Cytokine-activated IkappaB kinases essential for NF-kappaB activation. Science 278, 860\u2013866. https:\/\/doi.org\/10.1126\/science.278.5339.860 (1997).","journal-title":"Science"},{"key":"96660_CR31","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/nature01322","volume":"420","author":"LM Coussens","year":"2002","unstructured":"Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860\u2013867. https:\/\/doi.org\/10.1038\/nature01322 (2002).","journal-title":"Nature"},{"key":"96660_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.tibs.2004.11.009","volume":"30","author":"P Viatour","year":"2005","unstructured":"Viatour, P., Merville, M. P., Bours, V. & Chariot, A. Phosphorylation of NF-kappaB and IkappaB proteins: Implications in cancer and inflammation. Trends Biochem. Sci. 30, 43\u201352. https:\/\/doi.org\/10.1016\/j.tibs.2004.11.009 (2005).","journal-title":"Trends Biochem. Sci."},{"key":"96660_CR33","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s12943-019-0992-4","volume":"18","author":"Y Qu","year":"2019","unstructured":"Qu, Y. et al. Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment. Mol. Cancer 18, 69. https:\/\/doi.org\/10.1186\/s12943-019-0992-4 (2019).","journal-title":"Mol. Cancer"},{"key":"96660_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","volume":"34","author":"JG Doench","year":"2016","unstructured":"Doench, J. G. et al. Optimized SgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184\u2013191. https:\/\/doi.org\/10.1038\/nbt.3437 (2016).","journal-title":"Nat. Biotechnol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96660-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96660-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96660-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T07:54:03Z","timestamp":1743839643000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-96660-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,5]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["96660"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-96660-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,5]]},"assertion":[{"value":"15 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.S. received grant funding from the DFCI\/Novartis Drug Discovery Program and is a member of the SAB and has stock options with Auron Therapeutics on topics unrelated to this work. All other authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"11673"}}